HERMAB - 150MG
HERMAB - 150MG (ANTI CANCER DRUG)
PRODUCT DETAILS
Composition : Trastuzumab
Strength : 150mg
Manufactured by : RPG Life Sciences Ltd
Pack : two vials in a container; one vial containing drug Trastuzumab 1.0ml & one vial containing bacteriostatic water.
DESCRIPTION:
Hermab 150mg is a group of medicines which belongs to anti neoplastic medication. Hermab 150mg is a chemotherapy drug. It is recommended thatHermab 150mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.USES
The injectionHermab 150mg is used alone or combination with other medicine for the treatment in patients who suffering from metastatic breast cancer.The Hermab 150mg also indicated with combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.
WORK AS
Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.Hermab 150mg acts by adhere itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals, Hermab 150mg can slow or inhibit the growth of the breast cancer and the drug is an immune targeted therapy. In addition to inhibiting HER2 receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.
DOSAGE:
The injection Hermab 150mg should not mix with other drugs and do not administer as an intravenous push or bolus.
Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine
Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine
Adjuvant treatment, breast cancer:
The Hermab 150mg given according to one of the following doses and schedules for a 52 weeks total oftrastuzumab treatment:
During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV(intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Hermab 150mg dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.
The Hermab 150mg injection given as a single agent within three weeks following completion of multi-modality,
anthracycline-based chemotherapy regimens:
For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kgSuccessive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.
Metastatic Treatment, Breast Cancer:
Hermab 150mg administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.Metastatic Gastric Cancer:
Hermab 150mg administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.Embryo fetal damage
Hermab 150mg is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment
Cardiomyopathy
Patient getting Hermab 150mg injection have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinuingPulmonary toxicity
Some serious fatal cases of pulmonary toxicity occur during Hermab 150mg treatment.Infusion reactions
During Hermab 150mg treatment some life-threatening infusion reactions are produced. In serious infusion reactions, Stop theHermab 150mg treatment permanently. Patient should be treated with premedication before starting the infusion to overcome the such problem, During Hermab 150mg treatment. Use with Caution.Therapy induced neutropenia
Higher incidence of neutropenia occurs duringHermab 150mg treatment.DRUG INTERACTION
In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals.Do not take anthracycline treatment for 7 months after stopping the Hermab 150mg treatment.
Hermab 150mg interaction with anthracycline after ending of Hermab 150mg treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.
CONTRAINDICATION
Probably no contraindicated occurs. The patients are contraindicated to the component present in the Hermab 150mg Hence Hypersensitivity reactions are occurring.STORAGE
Store the Hermab 150mg at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Hermab 150mg diluted bag at 2℃ to 8℃ for 24 hours.MISSED DOSE
The Hermab 150mg Missing doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.SIDE EFFECTS
Common side effects:
Redness at injection site (IV)Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain
Serious side effects:
Increased coughingSudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing
Contact Details
Phone :+91-9987711567
Email :applepharmaceutical@gmail.com
 |
| Myapplepharma |
Email :info@myapplepharma.com
Comments
Post a Comment